<DOC>
	<DOCNO>NCT01986803</DOCNO>
	<brief_summary>This Prospective , randomize ( 1:1 ) , active control , single-blind , non-inferiority , European multicenter clinical trial . The primary objective study ass neointimal heal score ( evaluate intra-coronary OFDI ) patient ST-elevation Myocardial Infarction ( STEMI ) treat Abbott Vascular ABSORB everolimus elute bioresorbable vascular scaffold ( BVS ) 6 month follow-up compare metallic drug elute stent ( XIENCE ) . Furthermore , safety feasibility implant ABSORB BVS patient STEMI assess . It hypothesize acutely 6 month follow-up implantation ABSORB fully bioresorbable everolimus-eluting scaffold least safe implantation metallic drug-eluting stent , late follow-up ABSORB scaffold could improve arterial healing process potentially reduce late stent thrombosis patient present STEMI . This preparatory trial anticipation major outcome study .</brief_summary>
	<brief_title>ABSORB STEMI : TROFI II Study</brief_title>
	<detailed_description>A total 190 patient include trial , 8-10 European site . The primary endpoint arterial heal 6 month follow . To assess arterial healing , 6 month follow-up patient undergo angiographic follow-up OFDI investigation . To score arterial healing , Healing Score use .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>1 . Subject must least 18 year age ; 2 . Primary PCI within 24 hour symptom onset ; 3 . STsegment elevation &gt; 1mm &gt; 2 contiguous lead , ( presumably new ) leave bundle branch block , true posterior MI ST depression &gt; 1mm &gt; 2 contiguous anterior lead ; 4 . Presence least one acute infarct artery target vessel one coronary artery stenosis native coronary artery within plan device deployment segment ( Dmax ) visual estimation ≥ 2.5 mm ≤ 3.8 mm ; 5 . Subject agree participate investigational invasive clinical study period 6 month follow index procedure . 1 . Inability provide informed consent ; 2 . Known pregnancy time randomization . Female breastfeeding time randomization ; 3 . Known intolerance aspirin , heparin , PLLA ( poly ( Llactic acid ) , everolimus , contrast material ; 4 . Cardiogenic Shock ; 5 . Unprotected leave main coronary artery stenosis ; 6 . Distal occlusion target vessel ; 7 . Acute myocardial infarction secondary stent thrombosis ; 8 . Mechanical complication acute myocardial infarction ; 9 . Severe tortuous , calcify angulated coronary anatomy study vessel opinion investigator would result suboptimal image excessive risk complication placement OFDI catheter ; 10 . Fibrinolysis prior PCI ; 11 . Active bleeding coagulopathy patient chronic anticoagulation therapy ; 12 . Subject currently participate another clinical trial yet complete primary endpoint .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>ST-elevation Myocardial Infarction ( STEMI )</keyword>
	<keyword>Primary Percutaneous Coronary Intervention within 24 hr</keyword>
	<keyword>Healing score</keyword>
	<keyword>OFDI</keyword>
</DOC>